Washington D.C., DC Clinical Trials Report — April 2026

For residents of Washington D.C. considering participation in clinical research, April 2026 presents a critical window of opportunity, particularly for those looking to join studies before enrollment concludes. Across the District, 49 clinical trials are slated to close within the next 90 days. This urgency is especially relevant for healthy volunteers, as 7 of these rapidly closing studies are still actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly.

Upcoming Deadlines for Specific Conditions

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various cancers, neurological conditions, and metabolic disorders are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Stage IV Lung Cancer AJCC V8 (2 trials)
• Aged (1 trial)
• Anxiety Disorders (1 trial)
• Alzheimer Disease (1 trial)
• Anatomic Stage II Breast Cancer AJCC V8 (1 trial)
• Anatomic Stage III Breast Cancer AJCC V8 (1 trial)
• Agoraphobia (1 trial)
• Argi Deficiency (1 trial)
• Argininosuccinic Aciduria (1 trial)
• Arrythmia (1 trial)

This month, Washington D.C. saw the opening of 4 new clinical trials, a positive increase from the 2 trials that launched in March 2026. Despite the relatively small number of new openings compared to previous months (e.g., 15 in February 2026), the city continues to be an active center for medical research, with a total of 824 clinical trials currently recruiting across 294 research facilities.

Spotlight on New Research Opportunities

April brings several notable new trials to Washington D.C., including significant Phase 2 and 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Incyte Corporation is sponsoring NCT07522073, "A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma." This important Phase 3 oncology trial seeks 588 participants to evaluate the efficacy and safety of a new combination therapy for metastatic pancreatic cancer.
• Westat is launching NCT07510048, "Combatting HIV Or Other STIs Early (CHOOSE) in an RCT of mHealth Tool Support." This Phase 2 study, designed for 200 participants, aims to optimize and assess an mHealth tool's efficacy on PrEP initiation and adherence among young people for HIV and STI prevention.
• The National Institute of Allergy and Infectious Diseases (NIAID) is initiating NCT07549503, "Early Signals of the Transition From Immune Quiescence to Activation in the Liver Allograft Microenvironment and in the Circulation." This Phase 2 study, involving 100 participants, will investigate the efficacy of a 50 percent immunosuppression reduction in liver transplant recipients.

New trials this month are exploring a range of conditions, including HIV, HIV prevention, intracranial pressure, liver transplant, solid tumors, STIs, and STI prevention. One new trial is a DEVICE study, one is a DRUG trial, one is a PROCEDURE trial, and one falls under OTHER types of research. Of the 4 new trials, 3 include children, and 1 is specifically for male participants. One new trial also includes older adults.

For individuals without a specific medical condition, there are significant opportunities to contribute. 1 of the 4 new trials launched this month is actively seeking healthy volunteers. Across Washington D.C., a total of 92 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Washington D.C.'s Leading Research Hubs

Washington D.C. is home to several prominent research institutions that consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Children's National Medical Center (97 trials)
• MedStar Washington Hospital Center (66 trials)
• Children's National Hospital (64 trials)
• MedStar Georgetown University Hospital (62 trials)
• Sibley Memorial Hospital (45 trials)
• Georgetown University Medical Center (33 trials)
• Georgetown University (31 trials)
• Research Site (26 trials)
• George Washington University Medical Center (23 trials)
• Medstar Washington Hospital Center (23 trials)

These institutions offer a broad spectrum of research, from pediatric studies at Children's National Medical Center and Children's National Hospital, to diverse medical fields at MedStar Washington Hospital Center and Georgetown University Medical Center.

Broadening Your Search: Nearby Options

Based on the available data, there are no specific nearby cities with active trials listed for Washington D.C. at this time. Participants should focus their search within the District.

As we move further into spring, the focus will remain on the ongoing enrollment in these significant Phase 2 and 3 trials and the continued exploration of new therapeutic strategies, with Washington D.C.'s robust research community at the forefront of medical innovation.